NewHold Investment Corp IV Class A Ordinary Shares (NHIV) Stock Competitors & Peer Comparison

NHIV plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NHIV stands at 276.9M. In comparison, TPGXL has a market cap of 16.3B. Regarding current trading prices, NHIV is priced at $10.08, while TPGXL trades at $23.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NHIV currently has a P/E ratio of N/A, whereas TPGXL's P/E ratio is N/A. In terms of profitability, NHIV's ROE is N/A, compared to TPGXL's ROE of +0.13%. Regarding short-term risk, NHIV is less volatile compared to TPGXL. This indicates potentially lower risk in terms of short-term price fluctuations for NHIV.Check TPGXL's competition here

NHIV plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NHIV stands at 276.9M. In comparison, PACS has a market cap of 7.1B. Regarding current trading prices, NHIV is priced at $10.08, while PACS trades at $44.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NHIV currently has a P/E ratio of N/A, whereas PACS's P/E ratio is 38.18. In terms of profitability, NHIV's ROE is N/A, compared to PACS's ROE of +0.27%. Regarding short-term risk, NHIV is less volatile compared to PACS. This indicates potentially lower risk in terms of short-term price fluctuations for NHIV.Check PACS's competition here

NHIV plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NHIV stands at 276.9M. In comparison, BIPH has a market cap of 5.9B. Regarding current trading prices, NHIV is priced at $10.08, while BIPH trades at $16.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NHIV currently has a P/E ratio of N/A, whereas BIPH's P/E ratio is N/A. In terms of profitability, NHIV's ROE is N/A, compared to BIPH's ROE of +0.06%. Regarding short-term risk, NHIV is less volatile compared to BIPH. This indicates potentially lower risk in terms of short-term price fluctuations for NHIV.Check BIPH's competition here

NHIV plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NHIV stands at 276.9M. In comparison, TAKNX has a market cap of 2.3B. Regarding current trading prices, NHIV is priced at $10.08, while TAKNX trades at $8.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NHIV currently has a P/E ratio of N/A, whereas TAKNX's P/E ratio is N/A. In terms of profitability, NHIV's ROE is N/A, compared to TAKNX's ROE of N/A. Regarding short-term risk, NHIV is more volatile compared to TAKNX. This indicates potentially higher risk in terms of short-term price fluctuations for NHIV.Check TAKNX's competition here

NHIV plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NHIV stands at 276.9M. In comparison, MSDL has a market cap of 1.3B. Regarding current trading prices, NHIV is priced at $10.08, while MSDL trades at $15.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NHIV currently has a P/E ratio of N/A, whereas MSDL's P/E ratio is 7.92. In terms of profitability, NHIV's ROE is N/A, compared to MSDL's ROE of +0.05%. Regarding short-term risk, NHIV is less volatile compared to MSDL. This indicates potentially lower risk in terms of short-term price fluctuations for NHIV.Check MSDL's competition here

NHIV plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NHIV stands at 276.9M. In comparison, BBCQW has a market cap of 1.2B. Regarding current trading prices, NHIV is priced at $10.08, while BBCQW trades at $2.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NHIV currently has a P/E ratio of N/A, whereas BBCQW's P/E ratio is N/A. In terms of profitability, NHIV's ROE is N/A, compared to BBCQW's ROE of N/A. Regarding short-term risk, NHIV is less volatile compared to BBCQW. This indicates potentially lower risk in terms of short-term price fluctuations for NHIV.Check BBCQW's competition here

NHIV plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NHIV stands at 276.9M. In comparison, RILYK has a market cap of 787.6M. Regarding current trading prices, NHIV is priced at $10.08, while RILYK trades at $25.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NHIV currently has a P/E ratio of N/A, whereas RILYK's P/E ratio is N/A. In terms of profitability, NHIV's ROE is N/A, compared to RILYK's ROE of -2.63%. Regarding short-term risk, NHIV is more volatile compared to RILYK. This indicates potentially higher risk in terms of short-term price fluctuations for NHIV.Check RILYK's competition here

NHIV plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NHIV stands at 276.9M. In comparison, RILYM has a market cap of 753M. Regarding current trading prices, NHIV is priced at $10.08, while RILYM trades at $25.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NHIV currently has a P/E ratio of N/A, whereas RILYM's P/E ratio is N/A. In terms of profitability, NHIV's ROE is N/A, compared to RILYM's ROE of -2.63%. Regarding short-term risk, NHIV is more volatile compared to RILYM. This indicates potentially higher risk in terms of short-term price fluctuations for NHIV.Check RILYM's competition here

NHIV plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NHIV stands at 276.9M. In comparison, CCXI has a market cap of 678.8M. Regarding current trading prices, NHIV is priced at $10.08, while CCXI trades at $15.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NHIV currently has a P/E ratio of N/A, whereas CCXI's P/E ratio is N/A. In terms of profitability, NHIV's ROE is N/A, compared to CCXI's ROE of +0.00%. Regarding short-term risk, NHIV is less volatile compared to CCXI. This indicates potentially lower risk in terms of short-term price fluctuations for NHIV.Check CCXI's competition here

NHIV plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NHIV stands at 276.9M. In comparison, CCXIU has a market cap of 675.6M. Regarding current trading prices, NHIV is priced at $10.08, while CCXIU trades at $16.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NHIV currently has a P/E ratio of N/A, whereas CCXIU's P/E ratio is N/A. In terms of profitability, NHIV's ROE is N/A, compared to CCXIU's ROE of +0.00%. Regarding short-term risk, NHIV is less volatile compared to CCXIU. This indicates potentially lower risk in terms of short-term price fluctuations for NHIV.Check CCXIU's competition here

NHIV plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NHIV stands at 276.9M. In comparison, RILYO has a market cap of 573.5M. Regarding current trading prices, NHIV is priced at $10.08, while RILYO trades at $25.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NHIV currently has a P/E ratio of N/A, whereas RILYO's P/E ratio is N/A. In terms of profitability, NHIV's ROE is N/A, compared to RILYO's ROE of -2.63%. Regarding short-term risk, NHIV is more volatile compared to RILYO. This indicates potentially higher risk in terms of short-term price fluctuations for NHIV.Check RILYO's competition here

NHIV plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NHIV stands at 276.9M. In comparison, NWAX-UN has a market cap of 506.9M. Regarding current trading prices, NHIV is priced at $10.08, while NWAX-UN trades at $10.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NHIV currently has a P/E ratio of N/A, whereas NWAX-UN's P/E ratio is N/A. In terms of profitability, NHIV's ROE is N/A, compared to NWAX-UN's ROE of +0.01%. Regarding short-term risk, NHIV is more volatile compared to NWAX-UN. This indicates potentially higher risk in terms of short-term price fluctuations for NHIV.Check NWAX-UN's competition here

NHIV plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NHIV stands at 276.9M. In comparison, NWAX has a market cap of 504.7M. Regarding current trading prices, NHIV is priced at $10.08, while NWAX trades at $10.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NHIV currently has a P/E ratio of N/A, whereas NWAX's P/E ratio is N/A. In terms of profitability, NHIV's ROE is N/A, compared to NWAX's ROE of +0.01%. Regarding short-term risk, NHIV is more volatile compared to NWAX. This indicates potentially higher risk in terms of short-term price fluctuations for NHIV.Check NWAX's competition here

NHIV plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NHIV stands at 276.9M. In comparison, TMS has a market cap of 485.9M. Regarding current trading prices, NHIV is priced at $10.08, while TMS trades at $6.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NHIV currently has a P/E ratio of N/A, whereas TMS's P/E ratio is N/A. In terms of profitability, NHIV's ROE is N/A, compared to TMS's ROE of N/A. Regarding short-term risk, NHIV is less volatile compared to TMS. This indicates potentially lower risk in terms of short-term price fluctuations for NHIV.Check TMS's competition here

NHIV plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NHIV stands at 276.9M. In comparison, CRAN has a market cap of 477.2M. Regarding current trading prices, NHIV is priced at $10.08, while CRAN trades at $10.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NHIV currently has a P/E ratio of N/A, whereas CRAN's P/E ratio is N/A. In terms of profitability, NHIV's ROE is N/A, compared to CRAN's ROE of +0.01%. Regarding short-term risk, NHIV is more volatile compared to CRAN. This indicates potentially higher risk in terms of short-term price fluctuations for NHIV.Check CRAN's competition here

NHIV plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NHIV stands at 276.9M. In comparison, VACHU has a market cap of 475.5M. Regarding current trading prices, NHIV is priced at $10.08, while VACHU trades at $14.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NHIV currently has a P/E ratio of N/A, whereas VACHU's P/E ratio is N/A. In terms of profitability, NHIV's ROE is N/A, compared to VACHU's ROE of +0.04%. Regarding short-term risk, NHIV is more volatile compared to VACHU. This indicates potentially higher risk in terms of short-term price fluctuations for NHIV.Check VACHU's competition here

NHIV plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NHIV stands at 276.9M. In comparison, ANSCU has a market cap of 475.3M. Regarding current trading prices, NHIV is priced at $10.08, while ANSCU trades at $11.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NHIV currently has a P/E ratio of N/A, whereas ANSCU's P/E ratio is N/A. In terms of profitability, NHIV's ROE is N/A, compared to ANSCU's ROE of +0.03%. Regarding short-term risk, NHIV is less volatile compared to ANSCU. This indicates potentially lower risk in terms of short-term price fluctuations for NHIV.Check ANSCU's competition here

NHIV plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NHIV stands at 276.9M. In comparison, ANSC has a market cap of 475.3M. Regarding current trading prices, NHIV is priced at $10.08, while ANSC trades at $11.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NHIV currently has a P/E ratio of N/A, whereas ANSC's P/E ratio is 52.00. In terms of profitability, NHIV's ROE is N/A, compared to ANSC's ROE of +0.03%. Regarding short-term risk, NHIV is less volatile compared to ANSC. This indicates potentially lower risk in terms of short-term price fluctuations for NHIV.Check ANSC's competition here

NHIV plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NHIV stands at 276.9M. In comparison, LEGT-UN has a market cap of 467.4M. Regarding current trading prices, NHIV is priced at $10.08, while LEGT-UN trades at $18.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NHIV currently has a P/E ratio of N/A, whereas LEGT-UN's P/E ratio is N/A. In terms of profitability, NHIV's ROE is N/A, compared to LEGT-UN's ROE of +0.04%. Regarding short-term risk, NHIV is more volatile compared to LEGT-UN. This indicates potentially higher risk in terms of short-term price fluctuations for NHIV.Check LEGT-UN's competition here

NHIV plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NHIV stands at 276.9M. In comparison, CXIIU has a market cap of 450.9M. Regarding current trading prices, NHIV is priced at $10.08, while CXIIU trades at $10.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NHIV currently has a P/E ratio of N/A, whereas CXIIU's P/E ratio is N/A. In terms of profitability, NHIV's ROE is N/A, compared to CXIIU's ROE of N/A. Regarding short-term risk, NHIV is more volatile compared to CXIIU. This indicates potentially higher risk in terms of short-term price fluctuations for NHIV.Check CXIIU's competition here

NHIV plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NHIV stands at 276.9M. In comparison, CXII has a market cap of 443.4M. Regarding current trading prices, NHIV is priced at $10.08, while CXII trades at $10.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NHIV currently has a P/E ratio of N/A, whereas CXII's P/E ratio is N/A. In terms of profitability, NHIV's ROE is N/A, compared to CXII's ROE of N/A. Regarding short-term risk, NHIV is less volatile compared to CXII. This indicates potentially lower risk in terms of short-term price fluctuations for NHIV.Check CXII's competition here

NHIV plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NHIV stands at 276.9M. In comparison, DBCAU has a market cap of 437.9M. Regarding current trading prices, NHIV is priced at $10.08, while DBCAU trades at $10.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NHIV currently has a P/E ratio of N/A, whereas DBCAU's P/E ratio is N/A. In terms of profitability, NHIV's ROE is N/A, compared to DBCAU's ROE of N/A. Regarding short-term risk, NHIV is more volatile compared to DBCAU. This indicates potentially higher risk in terms of short-term price fluctuations for NHIV.Check DBCAU's competition here

NHIV plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NHIV stands at 276.9M. In comparison, MESH has a market cap of 432.1M. Regarding current trading prices, NHIV is priced at $10.08, while MESH trades at $10.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NHIV currently has a P/E ratio of N/A, whereas MESH's P/E ratio is N/A. In terms of profitability, NHIV's ROE is N/A, compared to MESH's ROE of N/A. Regarding short-term risk, NHIV is more volatile compared to MESH. This indicates potentially higher risk in terms of short-term price fluctuations for NHIV.Check MESH's competition here

NHIV plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NHIV stands at 276.9M. In comparison, ANSCW has a market cap of 425.4M. Regarding current trading prices, NHIV is priced at $10.08, while ANSCW trades at $0.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NHIV currently has a P/E ratio of N/A, whereas ANSCW's P/E ratio is N/A. In terms of profitability, NHIV's ROE is N/A, compared to ANSCW's ROE of +0.03%. Regarding short-term risk, NHIV is more volatile compared to ANSCW. This indicates potentially higher risk in terms of short-term price fluctuations for NHIV.Check ANSCW's competition here

NHIV plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NHIV stands at 276.9M. In comparison, XRPN has a market cap of 412.5M. Regarding current trading prices, NHIV is priced at $10.08, while XRPN trades at $10.44.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NHIV currently has a P/E ratio of N/A, whereas XRPN's P/E ratio is 80.38. In terms of profitability, NHIV's ROE is N/A, compared to XRPN's ROE of +0.05%. Regarding short-term risk, NHIV is less volatile compared to XRPN. This indicates potentially lower risk in terms of short-term price fluctuations for NHIV.Check XRPN's competition here

NHIV plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NHIV stands at 276.9M. In comparison, XRPNW has a market cap of 403.8M. Regarding current trading prices, NHIV is priced at $10.08, while XRPNW trades at $0.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NHIV currently has a P/E ratio of N/A, whereas XRPNW's P/E ratio is N/A. In terms of profitability, NHIV's ROE is N/A, compared to XRPNW's ROE of +0.05%. Regarding short-term risk, NHIV is less volatile compared to XRPNW. This indicates potentially lower risk in terms of short-term price fluctuations for NHIV.Check XRPNW's competition here

NHIV plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NHIV stands at 276.9M. In comparison, BBCQ has a market cap of 396.8M. Regarding current trading prices, NHIV is priced at $10.08, while BBCQ trades at $10.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NHIV currently has a P/E ratio of N/A, whereas BBCQ's P/E ratio is N/A. In terms of profitability, NHIV's ROE is N/A, compared to BBCQ's ROE of N/A. Regarding short-term risk, NHIV is more volatile compared to BBCQ. This indicates potentially higher risk in terms of short-term price fluctuations for NHIV.Check BBCQ's competition here

NHIV plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NHIV stands at 276.9M. In comparison, GUAC has a market cap of 391.9M. Regarding current trading prices, NHIV is priced at $10.08, while GUAC trades at $9.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NHIV currently has a P/E ratio of N/A, whereas GUAC's P/E ratio is N/A. In terms of profitability, NHIV's ROE is N/A, compared to GUAC's ROE of N/A. Regarding short-term risk, NHIV is more volatile compared to GUAC. This indicates potentially higher risk in terms of short-term price fluctuations for NHIV.Check GUAC's competition here

NHIV plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NHIV stands at 276.9M. In comparison, MBAV has a market cap of 390.3M. Regarding current trading prices, NHIV is priced at $10.08, while MBAV trades at $10.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NHIV currently has a P/E ratio of N/A, whereas MBAV's P/E ratio is 83.54. In terms of profitability, NHIV's ROE is N/A, compared to MBAV's ROE of +0.02%. Regarding short-term risk, NHIV is more volatile compared to MBAV. This indicates potentially higher risk in terms of short-term price fluctuations for NHIV.Check MBAV's competition here

NHIV plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NHIV stands at 276.9M. In comparison, FCRS-UN has a market cap of 368.2M. Regarding current trading prices, NHIV is priced at $10.08, while FCRS-UN trades at $10.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NHIV currently has a P/E ratio of N/A, whereas FCRS-UN's P/E ratio is N/A. In terms of profitability, NHIV's ROE is N/A, compared to FCRS-UN's ROE of +0.01%. Regarding short-term risk, NHIV is more volatile compared to FCRS-UN. This indicates potentially higher risk in terms of short-term price fluctuations for NHIV.Check FCRS-UN's competition here

NHIV plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NHIV stands at 276.9M. In comparison, CRANU has a market cap of 367.8M. Regarding current trading prices, NHIV is priced at $10.08, while CRANU trades at $10.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NHIV currently has a P/E ratio of N/A, whereas CRANU's P/E ratio is N/A. In terms of profitability, NHIV's ROE is N/A, compared to CRANU's ROE of +0.01%. Regarding short-term risk, NHIV is less volatile compared to CRANU. This indicates potentially lower risk in terms of short-term price fluctuations for NHIV.Check CRANU's competition here

NHIV plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NHIV stands at 276.9M. In comparison, CEPT has a market cap of 360.2M. Regarding current trading prices, NHIV is priced at $10.08, while CEPT trades at $11.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NHIV currently has a P/E ratio of N/A, whereas CEPT's P/E ratio is -107.09. In terms of profitability, NHIV's ROE is N/A, compared to CEPT's ROE of +0.01%. Regarding short-term risk, NHIV is less volatile compared to CEPT. This indicates potentially lower risk in terms of short-term price fluctuations for NHIV.Check CEPT's competition here

NHIV plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NHIV stands at 276.9M. In comparison, DMAAU has a market cap of 359.4M. Regarding current trading prices, NHIV is priced at $10.08, while DMAAU trades at $10.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NHIV currently has a P/E ratio of N/A, whereas DMAAU's P/E ratio is N/A. In terms of profitability, NHIV's ROE is N/A, compared to DMAAU's ROE of +0.03%. Regarding short-term risk, NHIV is more volatile compared to DMAAU. This indicates potentially higher risk in terms of short-term price fluctuations for NHIV.Check DMAAU's competition here

NHIV plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NHIV stands at 276.9M. In comparison, ARCI has a market cap of 355.1M. Regarding current trading prices, NHIV is priced at $10.08, while ARCI trades at $10.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NHIV currently has a P/E ratio of N/A, whereas ARCI's P/E ratio is -4378.26. In terms of profitability, NHIV's ROE is N/A, compared to ARCI's ROE of +0.00%. Regarding short-term risk, NHIV is more volatile compared to ARCI. This indicates potentially higher risk in terms of short-term price fluctuations for NHIV.Check ARCI's competition here

NHIV plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NHIV stands at 276.9M. In comparison, SDHIR has a market cap of 351M. Regarding current trading prices, NHIV is priced at $10.08, while SDHIR trades at $0.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NHIV currently has a P/E ratio of N/A, whereas SDHIR's P/E ratio is N/A. In terms of profitability, NHIV's ROE is N/A, compared to SDHIR's ROE of +0.01%. Regarding short-term risk, NHIV is more volatile compared to SDHIR. This indicates potentially higher risk in terms of short-term price fluctuations for NHIV.Check SDHIR's competition here

NHIV plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NHIV stands at 276.9M. In comparison, SBXE has a market cap of 349.8M. Regarding current trading prices, NHIV is priced at $10.08, while SBXE trades at $10.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NHIV currently has a P/E ratio of N/A, whereas SBXE's P/E ratio is 507.00. In terms of profitability, NHIV's ROE is N/A, compared to SBXE's ROE of -0.09%. Regarding short-term risk, NHIV is more volatile compared to SBXE. This indicates potentially higher risk in terms of short-term price fluctuations for NHIV.Check SBXE's competition here

NHIV plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NHIV stands at 276.9M. In comparison, PLMKW has a market cap of 348.4M. Regarding current trading prices, NHIV is priced at $10.08, while PLMKW trades at $0.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NHIV currently has a P/E ratio of N/A, whereas PLMKW's P/E ratio is N/A. In terms of profitability, NHIV's ROE is N/A, compared to PLMKW's ROE of +0.03%. Regarding short-term risk, NHIV is less volatile compared to PLMKW. This indicates potentially lower risk in terms of short-term price fluctuations for NHIV.Check PLMKW's competition here

NHIV plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NHIV stands at 276.9M. In comparison, SCPQW has a market cap of 336.6M. Regarding current trading prices, NHIV is priced at $10.08, while SCPQW trades at $0.62.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NHIV currently has a P/E ratio of N/A, whereas SCPQW's P/E ratio is N/A. In terms of profitability, NHIV's ROE is N/A, compared to SCPQW's ROE of N/A. Regarding short-term risk, NHIV is more volatile compared to SCPQW. This indicates potentially higher risk in terms of short-term price fluctuations for NHIV.Check SCPQW's competition here

NHIV plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NHIV stands at 276.9M. In comparison, MRCOU has a market cap of 333.7M. Regarding current trading prices, NHIV is priced at $10.08, while MRCOU trades at $10.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NHIV currently has a P/E ratio of N/A, whereas MRCOU's P/E ratio is N/A. In terms of profitability, NHIV's ROE is N/A, compared to MRCOU's ROE of N/A. Regarding short-term risk, NHIV is more volatile compared to MRCOU. This indicates potentially higher risk in terms of short-term price fluctuations for NHIV.Check MRCOU's competition here

NHIV plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NHIV stands at 276.9M. In comparison, ENHA has a market cap of 332.6M. Regarding current trading prices, NHIV is priced at $10.08, while ENHA trades at $2.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NHIV currently has a P/E ratio of N/A, whereas ENHA's P/E ratio is -9.57. In terms of profitability, NHIV's ROE is N/A, compared to ENHA's ROE of -0.86%. Regarding short-term risk, NHIV is less volatile compared to ENHA. This indicates potentially lower risk in terms of short-term price fluctuations for NHIV.Check ENHA's competition here

NHIV plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NHIV stands at 276.9M. In comparison, IACQU has a market cap of 330.7M. Regarding current trading prices, NHIV is priced at $10.08, while IACQU trades at $10.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NHIV currently has a P/E ratio of N/A, whereas IACQU's P/E ratio is N/A. In terms of profitability, NHIV's ROE is N/A, compared to IACQU's ROE of N/A. Regarding short-term risk, NHIV is more volatile compared to IACQU. This indicates potentially higher risk in terms of short-term price fluctuations for NHIV.Check IACQU's competition here

NHIV plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NHIV stands at 276.9M. In comparison, RREV has a market cap of 329.2M. Regarding current trading prices, NHIV is priced at $10.08, while RREV trades at $9.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NHIV currently has a P/E ratio of N/A, whereas RREV's P/E ratio is N/A. In terms of profitability, NHIV's ROE is N/A, compared to RREV's ROE of +0.00%. Regarding short-term risk, NHIV is more volatile compared to RREV. This indicates potentially higher risk in terms of short-term price fluctuations for NHIV.Check RREV's competition here

NHIV plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NHIV stands at 276.9M. In comparison, FERAR has a market cap of 326.1M. Regarding current trading prices, NHIV is priced at $10.08, while FERAR trades at $0.28.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NHIV currently has a P/E ratio of N/A, whereas FERAR's P/E ratio is N/A. In terms of profitability, NHIV's ROE is N/A, compared to FERAR's ROE of +0.02%. Regarding short-term risk, NHIV is less volatile compared to FERAR. This indicates potentially lower risk in terms of short-term price fluctuations for NHIV.Check FERAR's competition here

NHIV plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NHIV stands at 276.9M. In comparison, PACH has a market cap of 324.8M. Regarding current trading prices, NHIV is priced at $10.08, while PACH trades at $10.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NHIV currently has a P/E ratio of N/A, whereas PACH's P/E ratio is 34.23. In terms of profitability, NHIV's ROE is N/A, compared to PACH's ROE of +0.03%. Regarding short-term risk, NHIV is more volatile compared to PACH. This indicates potentially higher risk in terms of short-term price fluctuations for NHIV.Check PACH's competition here

NHIV plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NHIV stands at 276.9M. In comparison, VACI has a market cap of 317.2M. Regarding current trading prices, NHIV is priced at $10.08, while VACI trades at $10.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NHIV currently has a P/E ratio of N/A, whereas VACI's P/E ratio is N/A. In terms of profitability, NHIV's ROE is N/A, compared to VACI's ROE of +0.01%. Regarding short-term risk, NHIV is more volatile compared to VACI. This indicates potentially higher risk in terms of short-term price fluctuations for NHIV.Check VACI's competition here

NHIV plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NHIV stands at 276.9M. In comparison, SAC has a market cap of 316.2M. Regarding current trading prices, NHIV is priced at $10.08, while SAC trades at $10.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NHIV currently has a P/E ratio of N/A, whereas SAC's P/E ratio is N/A. In terms of profitability, NHIV's ROE is N/A, compared to SAC's ROE of +0.00%. Regarding short-term risk, NHIV is more volatile compared to SAC. This indicates potentially higher risk in terms of short-term price fluctuations for NHIV.Check SAC's competition here

NHIV plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NHIV stands at 276.9M. In comparison, DBCA has a market cap of 309.2M. Regarding current trading prices, NHIV is priced at $10.08, while DBCA trades at $10.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NHIV currently has a P/E ratio of N/A, whereas DBCA's P/E ratio is N/A. In terms of profitability, NHIV's ROE is N/A, compared to DBCA's ROE of N/A. Regarding short-term risk, NHIV is more volatile compared to DBCA. This indicates potentially higher risk in terms of short-term price fluctuations for NHIV.Check DBCA's competition here

NHIV plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NHIV stands at 276.9M. In comparison, LPBB has a market cap of 309M. Regarding current trading prices, NHIV is priced at $10.08, while LPBB trades at $10.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NHIV currently has a P/E ratio of N/A, whereas LPBB's P/E ratio is 35.83. In terms of profitability, NHIV's ROE is N/A, compared to LPBB's ROE of +0.04%. Regarding short-term risk, NHIV is more volatile compared to LPBB. This indicates potentially higher risk in terms of short-term price fluctuations for NHIV.Check LPBB's competition here

NHIV plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NHIV stands at 276.9M. In comparison, LPBBU has a market cap of 308.6M. Regarding current trading prices, NHIV is priced at $10.08, while LPBBU trades at $10.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NHIV currently has a P/E ratio of N/A, whereas LPBBU's P/E ratio is N/A. In terms of profitability, NHIV's ROE is N/A, compared to LPBBU's ROE of +0.04%. Regarding short-term risk, NHIV is more volatile compared to LPBBU. This indicates potentially higher risk in terms of short-term price fluctuations for NHIV.Check LPBBU's competition here

NHIV plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NHIV stands at 276.9M. In comparison, ALOVU has a market cap of 302.9M. Regarding current trading prices, NHIV is priced at $10.08, while ALOVU trades at $10.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NHIV currently has a P/E ratio of N/A, whereas ALOVU's P/E ratio is N/A. In terms of profitability, NHIV's ROE is N/A, compared to ALOVU's ROE of +0.01%. Regarding short-term risk, NHIV is less volatile compared to ALOVU. This indicates potentially lower risk in terms of short-term price fluctuations for NHIV.Check ALOVU's competition here

NHIV plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NHIV stands at 276.9M. In comparison, BCCQU has a market cap of 301.8M. Regarding current trading prices, NHIV is priced at $10.08, while BCCQU trades at $10.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NHIV currently has a P/E ratio of N/A, whereas BCCQU's P/E ratio is N/A. In terms of profitability, NHIV's ROE is N/A, compared to BCCQU's ROE of N/A. Regarding short-term risk, NHIV is more volatile compared to BCCQU. This indicates potentially higher risk in terms of short-term price fluctuations for NHIV.Check BCCQU's competition here

NHIV plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NHIV stands at 276.9M. In comparison, SVACW has a market cap of 300.5M. Regarding current trading prices, NHIV is priced at $10.08, while SVACW trades at $1.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NHIV currently has a P/E ratio of N/A, whereas SVACW's P/E ratio is N/A. In terms of profitability, NHIV's ROE is N/A, compared to SVACW's ROE of -5.09%. Regarding short-term risk, NHIV is less volatile compared to SVACW. This indicates potentially lower risk in terms of short-term price fluctuations for NHIV.Check SVACW's competition here

NHIV plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NHIV stands at 276.9M. In comparison, CAIIU has a market cap of 296.5M. Regarding current trading prices, NHIV is priced at $10.08, while CAIIU trades at $10.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NHIV currently has a P/E ratio of N/A, whereas CAIIU's P/E ratio is N/A. In terms of profitability, NHIV's ROE is N/A, compared to CAIIU's ROE of N/A. Regarding short-term risk, NHIV is more volatile compared to CAIIU. This indicates potentially higher risk in terms of short-term price fluctuations for NHIV.Check CAIIU's competition here

NHIV plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NHIV stands at 276.9M. In comparison, RILYT has a market cap of 289.2M. Regarding current trading prices, NHIV is priced at $10.08, while RILYT trades at $20.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NHIV currently has a P/E ratio of N/A, whereas RILYT's P/E ratio is 2.85. In terms of profitability, NHIV's ROE is N/A, compared to RILYT's ROE of -2.63%. Regarding short-term risk, NHIV is less volatile compared to RILYT. This indicates potentially lower risk in terms of short-term price fluctuations for NHIV.Check RILYT's competition here

NHIV plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NHIV stands at 276.9M. In comparison, RILYN has a market cap of 288.5M. Regarding current trading prices, NHIV is priced at $10.08, while RILYN trades at $24.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NHIV currently has a P/E ratio of N/A, whereas RILYN's P/E ratio is 1.55. In terms of profitability, NHIV's ROE is N/A, compared to RILYN's ROE of -2.63%. Regarding short-term risk, NHIV is more volatile compared to RILYN. This indicates potentially higher risk in terms of short-term price fluctuations for NHIV.Check RILYN's competition here

NHIV plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NHIV stands at 276.9M. In comparison, RILYG has a market cap of 287.9M. Regarding current trading prices, NHIV is priced at $10.08, while RILYG trades at $24.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NHIV currently has a P/E ratio of N/A, whereas RILYG's P/E ratio is 20.86. In terms of profitability, NHIV's ROE is N/A, compared to RILYG's ROE of -2.63%. Regarding short-term risk, NHIV is less volatile compared to RILYG. This indicates potentially lower risk in terms of short-term price fluctuations for NHIV.Check RILYG's competition here

NHIV plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NHIV stands at 276.9M. In comparison, ACAAU has a market cap of 287.6M. Regarding current trading prices, NHIV is priced at $10.08, while ACAAU trades at $10.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NHIV currently has a P/E ratio of N/A, whereas ACAAU's P/E ratio is N/A. In terms of profitability, NHIV's ROE is N/A, compared to ACAAU's ROE of +0.00%. Regarding short-term risk, NHIV is more volatile compared to ACAAU. This indicates potentially higher risk in terms of short-term price fluctuations for NHIV.Check ACAAU's competition here

NHIV plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NHIV stands at 276.9M. In comparison, RILYP has a market cap of 286.9M. Regarding current trading prices, NHIV is priced at $10.08, while RILYP trades at $14.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NHIV currently has a P/E ratio of N/A, whereas RILYP's P/E ratio is 88.02. In terms of profitability, NHIV's ROE is N/A, compared to RILYP's ROE of -2.63%. Regarding short-term risk, NHIV is less volatile compared to RILYP. This indicates potentially lower risk in terms of short-term price fluctuations for NHIV.Check RILYP's competition here

NHIV plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NHIV stands at 276.9M. In comparison, KPET has a market cap of 286.6M. Regarding current trading prices, NHIV is priced at $10.08, while KPET trades at $9.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NHIV currently has a P/E ratio of N/A, whereas KPET's P/E ratio is N/A. In terms of profitability, NHIV's ROE is N/A, compared to KPET's ROE of N/A. Regarding short-term risk, NHIV is more volatile compared to KPET. This indicates potentially higher risk in terms of short-term price fluctuations for NHIV.Check KPET's competition here

NHIV plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NHIV stands at 276.9M. In comparison, RILYL has a market cap of 283.2M. Regarding current trading prices, NHIV is priced at $10.08, while RILYL trades at $14.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NHIV currently has a P/E ratio of N/A, whereas RILYL's P/E ratio is 88.08. In terms of profitability, NHIV's ROE is N/A, compared to RILYL's ROE of -2.63%. Regarding short-term risk, NHIV is less volatile compared to RILYL. This indicates potentially lower risk in terms of short-term price fluctuations for NHIV.Check RILYL's competition here

NHIV plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NHIV stands at 276.9M. In comparison, RILY has a market cap of 281M. Regarding current trading prices, NHIV is priced at $10.08, while RILY trades at $7.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NHIV currently has a P/E ratio of N/A, whereas RILY's P/E ratio is 0.66. In terms of profitability, NHIV's ROE is N/A, compared to RILY's ROE of -2.63%. Regarding short-term risk, NHIV is less volatile compared to RILY. This indicates potentially lower risk in terms of short-term price fluctuations for NHIV.Check RILY's competition here

NHIV plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NHIV stands at 276.9M. In comparison, LPAAW has a market cap of 280.7M. Regarding current trading prices, NHIV is priced at $10.08, while LPAAW trades at $0.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NHIV currently has a P/E ratio of N/A, whereas LPAAW's P/E ratio is N/A. In terms of profitability, NHIV's ROE is N/A, compared to LPAAW's ROE of +0.07%. Regarding short-term risk, NHIV is more volatile compared to LPAAW. This indicates potentially higher risk in terms of short-term price fluctuations for NHIV.Check LPAAW's competition here

NHIV plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NHIV stands at 276.9M. In comparison, XCBE has a market cap of 279.8M. Regarding current trading prices, NHIV is priced at $10.08, while XCBE trades at $9.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NHIV currently has a P/E ratio of N/A, whereas XCBE's P/E ratio is N/A. In terms of profitability, NHIV's ROE is N/A, compared to XCBE's ROE of +0.00%. Regarding short-term risk, NHIV is more volatile compared to XCBE. This indicates potentially higher risk in terms of short-term price fluctuations for NHIV.Check XCBE's competition here

NHIV plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NHIV stands at 276.9M. In comparison, XSLL has a market cap of 274.9M. Regarding current trading prices, NHIV is priced at $10.08, while XSLL trades at $9.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NHIV currently has a P/E ratio of N/A, whereas XSLL's P/E ratio is N/A. In terms of profitability, NHIV's ROE is N/A, compared to XSLL's ROE of +0.00%. Regarding short-term risk, NHIV is more volatile compared to XSLL. This indicates potentially higher risk in terms of short-term price fluctuations for NHIV.Check XSLL's competition here

NHIV plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NHIV stands at 276.9M. In comparison, HVII has a market cap of 272.5M. Regarding current trading prices, NHIV is priced at $10.08, while HVII trades at $10.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NHIV currently has a P/E ratio of N/A, whereas HVII's P/E ratio is -484.72. In terms of profitability, NHIV's ROE is N/A, compared to HVII's ROE of +0.02%. Regarding short-term risk, NHIV is more volatile compared to HVII. This indicates potentially higher risk in terms of short-term price fluctuations for NHIV.Check HVII's competition here

NHIV plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NHIV stands at 276.9M. In comparison, HVIIU has a market cap of 272.5M. Regarding current trading prices, NHIV is priced at $10.08, while HVIIU trades at $10.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NHIV currently has a P/E ratio of N/A, whereas HVIIU's P/E ratio is N/A. In terms of profitability, NHIV's ROE is N/A, compared to HVIIU's ROE of +0.02%. Regarding short-term risk, NHIV is more volatile compared to HVIIU. This indicates potentially higher risk in terms of short-term price fluctuations for NHIV.Check HVIIU's competition here

NHIV plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NHIV stands at 276.9M. In comparison, HVIIR has a market cap of 272.1M. Regarding current trading prices, NHIV is priced at $10.08, while HVIIR trades at $0.37.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NHIV currently has a P/E ratio of N/A, whereas HVIIR's P/E ratio is -17.13. In terms of profitability, NHIV's ROE is N/A, compared to HVIIR's ROE of +0.02%. Regarding short-term risk, NHIV is less volatile compared to HVIIR. This indicates potentially lower risk in terms of short-term price fluctuations for NHIV.Check HVIIR's competition here

NHIV plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NHIV stands at 276.9M. In comparison, OSPRU has a market cap of 270.1M. Regarding current trading prices, NHIV is priced at $10.08, while OSPRU trades at $10.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NHIV currently has a P/E ratio of N/A, whereas OSPRU's P/E ratio is N/A. In terms of profitability, NHIV's ROE is N/A, compared to OSPRU's ROE of N/A. Regarding short-term risk, NHIV is more volatile compared to OSPRU. This indicates potentially higher risk in terms of short-term price fluctuations for NHIV.Check OSPRU's competition here

NHIV plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NHIV stands at 276.9M. In comparison, SOUL-UN has a market cap of 265.7M. Regarding current trading prices, NHIV is priced at $10.08, while SOUL-UN trades at $10.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NHIV currently has a P/E ratio of N/A, whereas SOUL-UN's P/E ratio is N/A. In terms of profitability, NHIV's ROE is N/A, compared to SOUL-UN's ROE of +0.03%. Regarding short-term risk, NHIV is more volatile compared to SOUL-UN. This indicates potentially higher risk in terms of short-term price fluctuations for NHIV.Check SOUL-UN's competition here

NHIV plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NHIV stands at 276.9M. In comparison, PLMK has a market cap of 264.2M. Regarding current trading prices, NHIV is priced at $10.08, while PLMK trades at $10.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NHIV currently has a P/E ratio of N/A, whereas PLMK's P/E ratio is 43.60. In terms of profitability, NHIV's ROE is N/A, compared to PLMK's ROE of +0.03%. Regarding short-term risk, NHIV is less volatile compared to PLMK. This indicates potentially lower risk in terms of short-term price fluctuations for NHIV.Check PLMK's competition here

NHIV plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NHIV stands at 276.9M. In comparison, GIXXU has a market cap of 262.5M. Regarding current trading prices, NHIV is priced at $10.08, while GIXXU trades at $10.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NHIV currently has a P/E ratio of N/A, whereas GIXXU's P/E ratio is N/A. In terms of profitability, NHIV's ROE is N/A, compared to GIXXU's ROE of +0.00%. Regarding short-term risk, NHIV is more volatile compared to GIXXU. This indicates potentially higher risk in terms of short-term price fluctuations for NHIV.Check GIXXU's competition here

NHIV plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NHIV stands at 276.9M. In comparison, TVACW has a market cap of 261.8M. Regarding current trading prices, NHIV is priced at $10.08, while TVACW trades at $0.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NHIV currently has a P/E ratio of N/A, whereas TVACW's P/E ratio is N/A. In terms of profitability, NHIV's ROE is N/A, compared to TVACW's ROE of +0.05%. Regarding short-term risk, NHIV is more volatile compared to TVACW. This indicates potentially higher risk in terms of short-term price fluctuations for NHIV.Check TVACW's competition here

NHIV plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NHIV stands at 276.9M. In comparison, SORN has a market cap of 261.7M. Regarding current trading prices, NHIV is priced at $10.08, while SORN trades at $9.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NHIV currently has a P/E ratio of N/A, whereas SORN's P/E ratio is N/A. In terms of profitability, NHIV's ROE is N/A, compared to SORN's ROE of +1.22%. Regarding short-term risk, NHIV is more volatile compared to SORN. This indicates potentially higher risk in terms of short-term price fluctuations for NHIV.Check SORN's competition here

NHIV plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NHIV stands at 276.9M. In comparison, ARTC has a market cap of 260.7M. Regarding current trading prices, NHIV is priced at $10.08, while ARTC trades at $9.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NHIV currently has a P/E ratio of N/A, whereas ARTC's P/E ratio is N/A. In terms of profitability, NHIV's ROE is N/A, compared to ARTC's ROE of N/A. Regarding short-term risk, NHIV is more volatile compared to ARTC. This indicates potentially higher risk in terms of short-term price fluctuations for NHIV.Check ARTC's competition here

NHIV plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NHIV stands at 276.9M. In comparison, ALOV has a market cap of 260M. Regarding current trading prices, NHIV is priced at $10.08, while ALOV trades at $9.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NHIV currently has a P/E ratio of N/A, whereas ALOV's P/E ratio is N/A. In terms of profitability, NHIV's ROE is N/A, compared to ALOV's ROE of +0.01%. Regarding short-term risk, NHIV is more volatile compared to ALOV. This indicates potentially higher risk in terms of short-term price fluctuations for NHIV.Check ALOV's competition here

NHIV plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NHIV stands at 276.9M. In comparison, CAES has a market cap of 257.8M. Regarding current trading prices, NHIV is priced at $10.08, while CAES trades at $10.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NHIV currently has a P/E ratio of N/A, whereas CAES's P/E ratio is -5035.00. In terms of profitability, NHIV's ROE is N/A, compared to CAES's ROE of N/A. Regarding short-term risk, NHIV is more volatile compared to CAES. This indicates potentially higher risk in terms of short-term price fluctuations for NHIV.Check CAES's competition here

NHIV plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NHIV stands at 276.9M. In comparison, DYNCW has a market cap of 256.3M. Regarding current trading prices, NHIV is priced at $10.08, while DYNCW trades at $0.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NHIV currently has a P/E ratio of N/A, whereas DYNCW's P/E ratio is -0.23. In terms of profitability, NHIV's ROE is N/A, compared to DYNCW's ROE of N/A. Regarding short-term risk, NHIV is less volatile compared to DYNCW. This indicates potentially lower risk in terms of short-term price fluctuations for NHIV.Check DYNCW's competition here

NHIV plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NHIV stands at 276.9M. In comparison, PTOR has a market cap of 255.9M. Regarding current trading prices, NHIV is priced at $10.08, while PTOR trades at $10.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NHIV currently has a P/E ratio of N/A, whereas PTOR's P/E ratio is N/A. In terms of profitability, NHIV's ROE is N/A, compared to PTOR's ROE of +0.00%. Regarding short-term risk, NHIV is less volatile compared to PTOR. This indicates potentially lower risk in terms of short-term price fluctuations for NHIV.Check PTOR's competition here

NHIV plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NHIV stands at 276.9M. In comparison, FACTU has a market cap of 255.4M. Regarding current trading prices, NHIV is priced at $10.08, while FACTU trades at $10.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NHIV currently has a P/E ratio of N/A, whereas FACTU's P/E ratio is N/A. In terms of profitability, NHIV's ROE is N/A, compared to FACTU's ROE of +0.03%. Regarding short-term risk, NHIV is more volatile compared to FACTU. This indicates potentially higher risk in terms of short-term price fluctuations for NHIV.Check FACTU's competition here

NHIV plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NHIV stands at 276.9M. In comparison, AACI has a market cap of 254.8M. Regarding current trading prices, NHIV is priced at $10.08, while AACI trades at $9.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NHIV currently has a P/E ratio of N/A, whereas AACI's P/E ratio is 496.78. In terms of profitability, NHIV's ROE is N/A, compared to AACI's ROE of +0.00%. Regarding short-term risk, NHIV is more volatile compared to AACI. This indicates potentially higher risk in terms of short-term price fluctuations for NHIV.Check AACI's competition here

NHIV plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NHIV stands at 276.9M. In comparison, KEYYU has a market cap of 253.4M. Regarding current trading prices, NHIV is priced at $10.08, while KEYYU trades at $10.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NHIV currently has a P/E ratio of N/A, whereas KEYYU's P/E ratio is N/A. In terms of profitability, NHIV's ROE is N/A, compared to KEYYU's ROE of N/A. Regarding short-term risk, NHIV is less volatile compared to KEYYU. This indicates potentially lower risk in terms of short-term price fluctuations for NHIV.Check KEYYU's competition here

NHIV plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NHIV stands at 276.9M. In comparison, HCICU has a market cap of 253.2M. Regarding current trading prices, NHIV is priced at $10.08, while HCICU trades at $10.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NHIV currently has a P/E ratio of N/A, whereas HCICU's P/E ratio is 43.78. In terms of profitability, NHIV's ROE is N/A, compared to HCICU's ROE of +0.00%. Regarding short-term risk, NHIV is more volatile compared to HCICU. This indicates potentially higher risk in terms of short-term price fluctuations for NHIV.Check HCICU's competition here

NHIV plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NHIV stands at 276.9M. In comparison, OIMAW has a market cap of 250M. Regarding current trading prices, NHIV is priced at $10.08, while OIMAW trades at $0.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NHIV currently has a P/E ratio of N/A, whereas OIMAW's P/E ratio is N/A. In terms of profitability, NHIV's ROE is N/A, compared to OIMAW's ROE of N/A. Regarding short-term risk, NHIV is less volatile compared to OIMAW. This indicates potentially lower risk in terms of short-term price fluctuations for NHIV.Check OIMAW's competition here

NHIV plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NHIV stands at 276.9M. In comparison, CAQ has a market cap of 248.1M. Regarding current trading prices, NHIV is priced at $10.08, while CAQ trades at $9.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NHIV currently has a P/E ratio of N/A, whereas CAQ's P/E ratio is N/A. In terms of profitability, NHIV's ROE is N/A, compared to CAQ's ROE of +9.93%. Regarding short-term risk, NHIV is more volatile compared to CAQ. This indicates potentially higher risk in terms of short-term price fluctuations for NHIV.Check CAQ's competition here

NHIV plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NHIV stands at 276.9M. In comparison, HCIC has a market cap of 247.6M. Regarding current trading prices, NHIV is priced at $10.08, while HCIC trades at $9.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NHIV currently has a P/E ratio of N/A, whereas HCIC's P/E ratio is 29.34. In terms of profitability, NHIV's ROE is N/A, compared to HCIC's ROE of +1.74%. Regarding short-term risk, NHIV is more volatile compared to HCIC. This indicates potentially higher risk in terms of short-term price fluctuations for NHIV.Check HCIC's competition here

NHIV plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NHIV stands at 276.9M. In comparison, LEGT has a market cap of 247.2M. Regarding current trading prices, NHIV is priced at $10.08, while LEGT trades at $9.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NHIV currently has a P/E ratio of N/A, whereas LEGT's P/E ratio is 72.34. In terms of profitability, NHIV's ROE is N/A, compared to LEGT's ROE of +0.04%. Regarding short-term risk, NHIV is less volatile compared to LEGT. This indicates potentially lower risk in terms of short-term price fluctuations for NHIV.Check LEGT's competition here

NHIV plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NHIV stands at 276.9M. In comparison, SBXE-UN has a market cap of 246M. Regarding current trading prices, NHIV is priced at $10.08, while SBXE-UN trades at $10.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NHIV currently has a P/E ratio of N/A, whereas SBXE-UN's P/E ratio is N/A. In terms of profitability, NHIV's ROE is N/A, compared to SBXE-UN's ROE of -0.09%. Regarding short-term risk, NHIV is more volatile compared to SBXE-UN. This indicates potentially higher risk in terms of short-term price fluctuations for NHIV.Check SBXE-UN's competition here

NHIV plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NHIV stands at 276.9M. In comparison, DRDBW has a market cap of 243.3M. Regarding current trading prices, NHIV is priced at $10.08, while DRDBW trades at $0.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NHIV currently has a P/E ratio of N/A, whereas DRDBW's P/E ratio is N/A. In terms of profitability, NHIV's ROE is N/A, compared to DRDBW's ROE of +0.02%. Regarding short-term risk, NHIV is less volatile compared to DRDBW. This indicates potentially lower risk in terms of short-term price fluctuations for NHIV.Check DRDBW's competition here

NHIV plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NHIV stands at 276.9M. In comparison, DRDB has a market cap of 243.2M. Regarding current trading prices, NHIV is priced at $10.08, while DRDB trades at $10.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NHIV currently has a P/E ratio of N/A, whereas DRDB's P/E ratio is N/A. In terms of profitability, NHIV's ROE is N/A, compared to DRDB's ROE of +0.02%. Regarding short-term risk, NHIV is more volatile compared to DRDB. This indicates potentially higher risk in terms of short-term price fluctuations for NHIV.Check DRDB's competition here

NHIV plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NHIV stands at 276.9M. In comparison, DRDBU has a market cap of 243.1M. Regarding current trading prices, NHIV is priced at $10.08, while DRDBU trades at $11.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NHIV currently has a P/E ratio of N/A, whereas DRDBU's P/E ratio is N/A. In terms of profitability, NHIV's ROE is N/A, compared to DRDBU's ROE of +0.02%. Regarding short-term risk, NHIV is more volatile compared to DRDBU. This indicates potentially higher risk in terms of short-term price fluctuations for NHIV.Check DRDBU's competition here

NHIV plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NHIV stands at 276.9M. In comparison, SSACU has a market cap of 241.9M. Regarding current trading prices, NHIV is priced at $10.08, while SSACU trades at $10.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NHIV currently has a P/E ratio of N/A, whereas SSACU's P/E ratio is N/A. In terms of profitability, NHIV's ROE is N/A, compared to SSACU's ROE of -0.05%. Regarding short-term risk, NHIV is more volatile compared to SSACU. This indicates potentially higher risk in terms of short-term price fluctuations for NHIV.Check SSACU's competition here

NHIV plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NHIV stands at 276.9M. In comparison, SAAQ has a market cap of 240M. Regarding current trading prices, NHIV is priced at $10.08, while SAAQ trades at $10.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NHIV currently has a P/E ratio of N/A, whereas SAAQ's P/E ratio is N/A. In terms of profitability, NHIV's ROE is N/A, compared to SAAQ's ROE of +0.00%. Regarding short-term risk, NHIV is less volatile compared to SAAQ. This indicates potentially lower risk in terms of short-term price fluctuations for NHIV.Check SAAQ's competition here

NHIV plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NHIV stands at 276.9M. In comparison, GSRVU has a market cap of 238.4M. Regarding current trading prices, NHIV is priced at $10.08, while GSRVU trades at $10.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NHIV currently has a P/E ratio of N/A, whereas GSRVU's P/E ratio is N/A. In terms of profitability, NHIV's ROE is N/A, compared to GSRVU's ROE of N/A. Regarding short-term risk, NHIV is more volatile compared to GSRVU. This indicates potentially higher risk in terms of short-term price fluctuations for NHIV.Check GSRVU's competition here

NHIV plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NHIV stands at 276.9M. In comparison, MACI has a market cap of 236.8M. Regarding current trading prices, NHIV is priced at $10.08, while MACI trades at $10.93.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NHIV currently has a P/E ratio of N/A, whereas MACI's P/E ratio is 43.57. In terms of profitability, NHIV's ROE is N/A, compared to MACI's ROE of +0.03%. Regarding short-term risk, NHIV is less volatile compared to MACI. This indicates potentially lower risk in terms of short-term price fluctuations for NHIV.Check MACI's competition here

NHIV plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NHIV stands at 276.9M. In comparison, IRHO has a market cap of 236.6M. Regarding current trading prices, NHIV is priced at $10.08, while IRHO trades at $10.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NHIV currently has a P/E ratio of N/A, whereas IRHO's P/E ratio is 251.00. In terms of profitability, NHIV's ROE is N/A, compared to IRHO's ROE of +0.02%. Regarding short-term risk, NHIV is more volatile compared to IRHO. This indicates potentially higher risk in terms of short-term price fluctuations for NHIV.Check IRHO's competition here

NHIV plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NHIV stands at 276.9M. In comparison, ILLU has a market cap of 234.4M. Regarding current trading prices, NHIV is priced at $10.08, while ILLU trades at $9.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NHIV currently has a P/E ratio of N/A, whereas ILLU's P/E ratio is N/A. In terms of profitability, NHIV's ROE is N/A, compared to ILLU's ROE of N/A. Regarding short-term risk, NHIV is less volatile compared to ILLU. This indicates potentially lower risk in terms of short-term price fluctuations for NHIV.Check ILLU's competition here

NHIV plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NHIV stands at 276.9M. In comparison, BLRK has a market cap of 230.9M. Regarding current trading prices, NHIV is priced at $10.08, while BLRK trades at $10.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NHIV currently has a P/E ratio of N/A, whereas BLRK's P/E ratio is N/A. In terms of profitability, NHIV's ROE is N/A, compared to BLRK's ROE of N/A. Regarding short-term risk, NHIV is more volatile compared to BLRK. This indicates potentially higher risk in terms of short-term price fluctuations for NHIV.Check BLRK's competition here

NHIV plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NHIV stands at 276.9M. In comparison, ADAC has a market cap of 230.7M. Regarding current trading prices, NHIV is priced at $10.08, while ADAC trades at $10.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NHIV currently has a P/E ratio of N/A, whereas ADAC's P/E ratio is N/A. In terms of profitability, NHIV's ROE is N/A, compared to ADAC's ROE of +0.01%. Regarding short-term risk, NHIV is less volatile compared to ADAC. This indicates potentially lower risk in terms of short-term price fluctuations for NHIV.Check ADAC's competition here

NHIV plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NHIV stands at 276.9M. In comparison, VHCP has a market cap of 230M. Regarding current trading prices, NHIV is priced at $10.08, while VHCP trades at $9.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NHIV currently has a P/E ratio of N/A, whereas VHCP's P/E ratio is N/A. In terms of profitability, NHIV's ROE is N/A, compared to VHCP's ROE of N/A. Regarding short-term risk, NHIV is more volatile compared to VHCP. This indicates potentially higher risk in terms of short-term price fluctuations for NHIV.Check VHCP's competition here